BioVaxys and SpayVac-for-Wildlife Expand License Agreement to Target Aquaculture Market

BioVaxys Technology Corp. and SpayVac-for-Wildlife have broadened their collaborative efforts by expanding their existing license agreement to include commercial aquaculture and farm-raised fish markets. This strategic move significantly enhances the potential global revenue for SpayVac's innovative fertility-control vaccine technology.

The expanded agreement introduces a novel approach to reproductive control in aquaculture, offering an alternative to current genetic manipulation techniques like triploidy. SpayVac's immunocontraceptive vaccine requires only a single dose, presenting a potentially scalable and cost-effective solution for fish producers worldwide.

Thomas D'Orazio, CEO of SpayVac-for-Wildlife, emphasized the substantial market potential, noting that the vaccine provides producers with an efficient method for managing fish population and reproduction. The technology represents a potential paradigm shift in aquaculture management, moving beyond traditional genetic sterility methods.

This expansion builds upon SpayVac's existing portfolio of no-booster fertility-control vaccines, which already target various markets including feral, wild, invasive, and select production and companion animals. By incorporating commercial aquaculture, the company significantly broadens its potential market reach and revenue streams.

The development highlights the ongoing innovation in agricultural and animal health technologies, demonstrating how specialized biotechnology firms are creating targeted solutions for complex reproductive management challenges across different species and industries.